The Novo and Immunocore-backed cancer treatment developer has targeted $150m from a Nasdaq IPO, filing seven months after a $104m series A round.
UK-based biopharmaceutical company Adaptimmune Therapeutics, which counts pharmaceutical firm Novo among its investors, filed for an initial public offering in the US on Monday that could raise up to $150m.
Adaptimmune is developing cancer treatments based on its T-cell receptor platform, which could hypothetically enable it to genetically engineer T-cell receptors it could administer to patients in drug form.
The filing comes seven months after Adaptimmune raised $104m from a series A round backed by Novo, as well as New…
